NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Free Report) major shareholder St Co. Ltd Dong-A bought 2,544,530 shares of the company’s stock in a transaction that occurred on Sunday, June 23rd. The shares were bought at an average price of $3.13 per share, for a total transaction of $7,964,378.90. Following the completion of the acquisition, the insider now owns 5,348,229 shares in the company, valued at approximately $16,739,956.77. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
NeuroBo Pharmaceuticals Stock Performance
Shares of NASDAQ NRBO opened at $4.83 on Thursday. NeuroBo Pharmaceuticals, Inc. has a fifty-two week low of $2.89 and a fifty-two week high of $6.75. The business has a 50 day moving average price of $3.88 and a two-hundred day moving average price of $4.10.
NeuroBo Pharmaceuticals (NASDAQ:NRBO – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.37). As a group, sell-side analysts expect that NeuroBo Pharmaceuticals, Inc. will post -4.89 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals Company Profile
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.
See Also
- Five stocks we like better than NeuroBo Pharmaceuticals
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- 3 Stocks to Consider Buying in October
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Earnings Per Share Calculator: How to Calculate EPS
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.